Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2014-01-31
2019-11-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Saliva and Plasma Endocannabinoids Concentrations According to Feeding Status and Body Mass Index
NCT01223157
Implications of Circadian Variation of Human Endocannabinoid Levels on Obesity Risk
NCT03000803
Relation Between Pregnenolone Endocannabinoids in Normal-weight and Obese Men
NCT03157778
Profiling the Endocannabinoid Response to Hedonic Eating
NCT03113474
Biobehavioral Reward Responses Associated With Consumption of Nutritionally Diverse Ultra-Processed Foods
NCT05437809
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The present study is expected to begin mid-November 2013 for a total duration of 24 consecutive months. A sample of 25 patients suffering from obesity will be recruited and compared with 25 healthy normal volunteers who are free from any previous or current metabolic and psychiatric disorders. They will be matched on age and sex. They will be screened using the "Association pour la Méthodologie et la Documentation en Psychiatrie" questionnaire for obtaining a series of information, comprising the marital status, number of children, number of siblings, education and training, professional qualifications, significant life events… They will be evaluated with the Mini-International Neuropsychiatric Interview in order to determine the presence of mood disorders and associated psychopathology. The Three-Factor Eating Questionnaire will be employed for measuring three separate aspects of eating behavior: cognitive restraint, uncontrolled eating, and emotional eating. This will be completed with the Multidimensional Body Self-Relations Questionnaire and the State-Trait Anxiety Inventory in order to assess the body satisfaction and anxiety levels, respectively. Beyond all these assessments, two separate experimental sessions will be conducted, one in satiety and the other in fasting. During each session, the participants will be asked to perform the two validated instrumental tasks in front the screen of a computer. Plasma levels of endocannabinoids will be monitered by collecting blood samples prior to the consumption of a calorically-defined meal and while carrying out the computer-generated tasks under satiety. Blood will be withdrawn at the same time-points during the session in fasting. Visual analogue scales (VAS) assessing hunger levels will be completed before blood is collected. A VAS will be also used for the global assessment of appetitive properties of the viewed food images just before the end of the second experimental session.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
SCREENING
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Obese patients
Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels
Computer-based tasks
Computer-based tasks designed to assess size and time discrimination capacities
Blood sampling
Blood drawn for the measurement of circulating endocannabinoids concentrations
Normal-weight healthy volunteers
Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels
Computer-based tasks
Computer-based tasks designed to assess size and time discrimination capacities
Blood sampling
Blood drawn for the measurement of circulating endocannabinoids concentrations
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Computer-based tasks
Computer-based tasks designed to assess size and time discrimination capacities
Blood sampling
Blood drawn for the measurement of circulating endocannabinoids concentrations
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Be between 18 and 60 year-old
2. Have a body mass index ranging from 35 to 50 kg/m2
3. Have no previous history of surgical treatment of obesity
4. Have received no standard intervention for obesity within the last 3 months before study
5. Have a stable weight (variation \<5%) within the last 3 months before study
6. Have a restriction score \<9 on the three-factor eating questionnaire
7. Be free from any current and previous psychiatric disorder, such as major depression or drug abuse/dependence
8. Understand and accept the design and constraints of the present study
9. Be a beneficiary or member of health insurance plan
10. Provide written consent to the study after receiving clear information
Healthy volunteers :
1. Be between 18 and 60 year-old
2. Be free from any current and previous psychiatric disorder, such as major depression or drug abuse/dependence
3. Understand and accept the design and constraints of the present study
4. Be a beneficiary or member of health insurance plan
5. Provide written consent to the study after receiving clear information
Exclusion Criteria
1. Suffer from monogenic obesity
2. Take any psychotropic treatment such as anxiolytic/hypnotic drugs over the last week preceding the study
3. Be a pregnant or nursing woman
4. Use alcohol over the last two days preceding the study
Healthy volunteers :
1. Suffer from any current and previous somatic or psychiatric condition
2. Have a body mass index below 18,5 kg/m2 or above 25 kg/m2
3. Take any psychotropic treatment such as anxiolytic/hypnotic drugs over the last week preceding the study
4. Be a pregnant or nursing woman
5. Use alcohol over the last two days preceding the study
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bruno Aouizerate, Professor
Role: PRINCIPAL_INVESTIGATOR
Neurocentre Magendie (INSERM U862)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Neurocentre Magendie (INSERM U862)
Bordeaux, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-A00982-43
Identifier Type: REGISTRY
Identifier Source: secondary_id
C13-33
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.